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Cervical cancer and other human papillomavirus- (HPV-) related cancers are preventable, but preventive measures implemented
in developing countries and especially in low-income rural regions have not been eﬀective. Cervical cancer burden derived from
sexually transmitted HPV infections is the heaviest in developing countries, and a dramatic increase in the number of cervical
cancer cases is predicted, if no intervention is implemented in the near future. HPV vaccines oﬀer an eﬃcient way to prevent
related cancers. Recently implemented school-based HPV vaccination demonstration programmes can help tackle the challenges
linkedwithvaccinecoverage,andaccesstovaccinationandhealthservices,butpreventionstrategiesneedtobemodiﬁedaccording
to regional characteristics. In urban regions WHO-recommended vaccination strategies might be enough to signiﬁcantly reduce
HPV-related disease burden, but in the rural regions additional vaccination strategies, vaccinating both sexes rather than only
females when school attendance is the highest and applying a two-dose regime, need to be considered. From the point of view of
both public health and ethics identiﬁcation of the most eﬀective prevention strategies is pivotal, especially when access to health
services is limited. Considering cost-eﬀectiveness versus justice further research on optional vaccination strategies is warranted.
1.Background
1.1. Human Papillomavirus and Cervical Cancer. Human
papillomavirus (HPV) is the main cause of cervical cancer
[1], the third most common cancer in women [2]. There is,
however, growing evidence linking genital HPV infection to
other anogenital cancers (anus, vulva, vagina, and penis) and
headand neck cancersin both men and women[3–11].HPV
is carried by both females and males and can spread with
high (up to 0,6 per act for HPV16) transmission probability
[12], and most (up to 70–80%) people will get infected
during their lifetime [13]. Thus, HPV can be characterised
as a ubiquitous, sexually transmitted infection (STI) causing
signiﬁcant disease burden in both sexes, but especially in
women with up to 6-7% lifetime risk of developing cervical
cancer in Latin America [14].
Of the estimated 530000 annual cases of cervical cancer,
86% occur in developing countries [2]. Its standardised
incidence ratio (world, 100) is substantially higher in the
developing countries (116) than in the developed countries
(60). It is important to note that cervical cancer is the
most common cancer in women in most parts of Africa,
Central America, Southern Asia, and Melanesia. [3]I ti s
also the most important cause of years of life lost in Latin
America and the Caribbean, and among cancers in the
populous regions of Sub-Saharan Africa and South-Central
Asia [14]. Furthermore, largely due to changes in sexual
risk taking behaviour and (in some countries) dynamic state
of epidemics by high-risk (hr) HPV types [15, 16], the
number of cervical cancer cases has been predicted to rapidly
increase (up to 90%) by 2020 in developing countries if no
intervention is implemented [17, 18].
1.2. Occurrence of Other HPV-Related Cancers. It has been
established that the HPV attributable proportion in cancers
of the anus, vagina, penis, vulva, oropharynx, and oral cavity2 Infectious Diseases in Obstetrics and Gynecology
is 25% or higher [8, 11, 19–21]. There are clear signs that
the incidence of most HPV-related cancers is increasing.
The incidence rates of anal cancer in Scotland and England
have nearly doubled in both women and men from 1986 to
2003 [22]. Increase in the incidence of anal cancer is also
reported in Australia [23]. In the developed countries, also
the incidence of HPV-related head and neck cancer is rapidly
increasing especially in males and in the younger birth
cohorts [5, 6, 9–11, 24]. In Australia, Netherlands, Sweden,
and USA, the incidence of HPV-related tonsillar cancer
has rapidly increased during recent years [7, 23, 25, 26].
Similar trends have not yet been reported for the developing
countries.
1.3.OccurrenceofInfectionswithHigh-RiskHPVTypes. Most
of the genital infections with hrHPV type(s) are asymp-
tomatic and heal without treatment. The risk of cervical
cancer increases as the hrHPV infection persists. Over 70%
of cervical cancers are attributed to HPV types 16 and 18
and approximately 20% to HPV types 31, 33, 35, 45, 52,
and 58 [3, 27]. Precancerous cervical lesions usually appear
within 5 years in individuals with an established persistent
infection with HPV types 16 and 18. A majority of other
HPV-related cancers are also attributable to HPV types 16
and 18. For example, it is estimated that 24% of cancers
in the mouth are associated with HPV and 95% of these
cancers are attributable to HPV types 16 and 18. Over 80%
of anal cancers are associated with HPV and 92% of these
cancers are attributable to HPV types 16 and 18. Thus, it
can be assumed that targeting HPV types 16 and 18 and
a remarkable proportion of phylogenetically related hrHPV
types (31, 33, 45) by prophylactic vaccination [28–30]w o u l d
play a signiﬁcant role in preventing all HPV-related cancers
[27].
Prevention of hrHPV infections could decrease the
incidence of numerous cancers in both sexes [5, 31]. In
healthy men, HPV infection in the genital tract is very
common (from 35% to 73%) [32]. Alike other STIs, HPV
transmits more easily from men to women than from
women to men [3]. Male circumcision and use of condoms
prevent the spreading of hrHPV infections, which probably
explains the low incidence of cervical cancer in countries
such as Israel where circumcision is widespread [3, 33].
Racial diﬀerences have been reported showing that African-
Americans are less likely to have HPV-positive head and
neck(oropharyngeal)cancers[34,35].Reasonsfortherecent
increase of oropharyngeal HPV-related cancers, especially
in younger male birth cohorts in the developed countries,
are not clear, but changes in sexual behaviour, eﬃciency of
HPV transmission through oral sex, and lack of protective
immunity from hrHPV infections of the genital mucosae
have been suggested [6, 36].
Various studies indicate that a high number of lifetime
sexual partners, tobacco smoking, parity, oral contraceptive
use, and coinfections with Chlamydia trachomatis and HIV
increase the risk of acquisition of hrHPV infection [37–42].
The impact of cofactors on the acquisition of infections with
multiple hrHPV types has not been studied largely [43, 44].
STIs are a serious health problem in developing coun-
tries, and several studies indicate that conventional STIs
increase the likelihood of HIV transmission [45]. HPV
infections in both females and males are also risk factors
for HIV acquisition [46–48]. Prevention of HPV infections
could play a part in preventing other STIs as well [49]. It is
alsohighlylikelythatHPV-relatedneoplasiaprogressesfaster
in HIV-positive people [50].
2. Prevention of HPV-Related Cancers
2.1. HPV-Related Cancers and Cancer Mortality Are Pre-
ventable. Cervicalcancerisadiseasewhichcanbeprevented.
Similar to liver cancer that is secondary to hepatitis B
infection, cervical cancer has a recognized, single necessary
cause, HPV. Application of cervical cytology in population-
based screening programmes has signiﬁcantly lowered the
incidence of cervical cancer in developed countries [3].
Cervical cancer incidence and mortality decreased markedly
in the Nordic countries, Europe, Canada, and USA due to
the implementation of cervical cytology in health care, most
notably in population-based screening programmes [51–
54]. Mortality from cervical cancer has also substantially
declined since the 1960s in Europe, but there are still large
country-speciﬁc diﬀerences [55]. Cervical cancer mortality
is substantially higher in Eastern Europe than in other parts
of Europe. Increases in the incidence of and mortality from
cervical cancer have been reported in the last 15 years
resulting from HPV epidemics and a drop in the number of
women participating in the screening programmes [55].
Mortalityratesofcervicalcancerarelowerthanincidence
rates with a ratio of mortality to incidence of 55% [3].
Survivalratesare,however,lowerinthedevelopingcountries
[56–58], and the diﬀerences in the ratios of mortality to
incidence between developing and developed countries are
signiﬁcant.Theratiosrangefrom20%inSwitzerlandto80%
in most African countries. Latin America and South Asia
have ratios of 40–55% [3]. The diﬀerences can be explained
by the stage at which cancer is detected, access to health
services, and adequacy of treatment.
2.2. New Means for Primary Prevention of HPV-Related
Cancer. Currently there are two licensed prophylactic HPV
vaccines, a bivalent vaccine (Cervarix) against HPV types
16 and 18 and a quadrivalent (Gardasil) vaccine against
HPV types 6, 11, 16, and 18 available (FDA 2006; EMEA
2007). In order to be prophylactic, both vaccines need to
be administered before the individual is exposed to HPV
types covered by the vaccine. According to reports from
the major phase III trials, the vaccines prevent from 97 to
98% of infections caused by HPV types 16 and 18 [59, 60].
Both vaccines have shown a signiﬁcant cross-protection also
against HPV types 31 and 45 [28, 29]. The bivalent vaccine
has also shown cross-protection against HPV types 33 and
51 [30]. As indicated above, over 70% of cervical cancers
are attributed to HPV types 16 and 18, and approximately
20% to HPV types 31, 33, 35, 45, 52, and 58 [3, 27]w h i c h
ﬁts the cross-protection eﬃcacy and reported 87% overallInfectious Diseases in Obstetrics and Gynecology 3
vaccine eﬃcacy against CIN3+ [29]. It is assumed that both
HPVvaccines,inpreventinghrHPVinfections,preventother
HPV-related cancers besides cervical cancer with high to
moderate eﬃcacy [61].
Itisknownthattheexistingvaccinesaremosteﬃcientfor
antibodyproductionwhenadministeredtoearlyadolescents.
Both males and females had higher antibody responses at
the age of 9–15 compared to the age of 16–26 [62, 63].
There is, however, no concrete information available on
long-term (>10 years) eﬃcacy of the vaccines and necessity
for a booster. One model has predicted an over 20-year
protection but at the moment the predictions rely only on
assumptions [64]. It is not known if HIV infection will aﬀect
the eﬃcacy of HPV vaccines [65], but smoking does not
seem to aﬀect HPV vaccine-induced antibody response [42].
Booster doses work very well and produce higher antibody
levels when measured one month later [62]. HIV positivity
as such does not hamper development of HPV antibodies
following natural infection [66], whereas smoking does [42].
Typereplacement,thatis,hownontargetedhrHPVtypesthat
may have competitive advantage [67] will behave following
mass vaccination, is an open question, but the likelihood
of the kind of type replacement seen following bacterial
vaccination is small due to the diﬀerent biology of viral and
bacterial infections [68, 69].
3. PrimaryPreventionStrategiesin
DevelopedCountries
According to WHO, 22 countries in low-resource regions
have included an HPV vaccine in their vaccine programmes
[70]. Adopted vaccination strategies include oﬀering the
vaccine only to 12–15-year-old girls or only to a certain pro-
portion of the female population of the same age. The vacci-
nationstrategiesareinlinewiththeresultsofnumerouscost-
eﬀectiveness studies which suggest that with high vaccine
coverage (≥75%) vaccination of males would not be cost
eﬀective[71–82].Vaccinatingmalesbecomescosteﬀectiveby
assuming a low to moderate (30%–50%) coverage in females
[74].
The assumptions behind these recommendations and
the superior cost-eﬀectiveness of female vaccination strategy
are that the health service system covers all the regions
equitably and that adolescent girls have both access to
the health services and are willing to use it. However, the
probability of preventing other HPV-related cancers both in
femalesandmaleshasnotbeentakenintoaccount.Emerging
information on HPV-related cancers in men may change the
conclusions of cost-eﬀectiveness modelling. In Australia, it is
estimated that one quarter of the preventable cancers are in
men [23], but this most likely varies between countries.
There is not enough information on how vaccinating
males would change the transmission of HPV, but it is
possible that vaccinating only females could result in an
increase in HPV transmission like in the case of Rubella
vaccination and Rubella acquisition by young adult females
in the UK [83]. British data also suggests that due to sexual
behaviour characteristics British men are at greater risk
of being exposed to, contracting, and transmitting HPV
infectionthanfemales.Eachvaccinatedmalewouldtherefore
reduce the infection risk more than a vaccinated female
[84]. It is important to estimate if this assumption is true,
and the extent of the possible diﬀerence. Overall, the highly
infectious nature (high transmission probability) of HPV
supports the idea of vaccinating both sexes. It is also possible
that vaccinating the same number of males and females as
in the female-only vaccination strategy would decrease the
prevalence of hrHPV infections slightly in a steady state of
hrHPV epidemics [85] and in dynamic state of the hrHPV
epidemics (as is the case in many countries), and it is likely
that the impact of male vaccination would be higher.
The questions concerning HPV vaccine eﬃcacy on males
and the possible eﬀect of vaccination on HPV transmission
are valid as it is known that the vaccine against herpes sim-
plexvirustype2isnoteﬀectiveonmales[86]butitcouldstill
have a profound eﬀect on HSV-2 occurrence through herd
immunity provided viral shedding is signiﬁcantly reduced
[87]. Prevention of infectious diseases comparable to HPV
with vaccines is based on producing herd immunity through
as u ﬃcient coverage in susceptible individuals to reduce
transmission [87]. The quadrivalent HPV vaccine is proven
eﬃcacious in males, likely prevents HPV transmission [88],
and has been shown to reduce HPV 6/11-associated disease
burden. Vaccinating males is currently not recommended
by the WHO, but the impact of herd immunity on female
cancers and other HPV-related cancers may need to be
reconsidered [89, 90].
High vaccine coverage is needed to produce herd immu-
nity, and the key question is whether suﬃcient coverage can
be achieved by vaccinating only females. Suﬃcient coverage
hasbeenachievedonlyintheUK(75%)andAustralia(70%).
In the Netherlands (50%), Germany (40%), and USA (25%),
the coverage is neither enough to protect signiﬁcant propor-
tions of females nor to produce herd immunity. Protection
is eﬀective on an individual level, but in the absence of
herd immunity the unvaccinated remain unprotected. At
present, the questions concerning coverage in both sexes and
the magnitude of herd immunity remain open [65, 87, 90].
Mathematical models suggest that vaccinating both males
and females could produce herd immunity and an impact
both on hrHPV prevalence and occurrence of cervical cancer
with considerably lower coverage than vaccinating females
only [12, 89, 90]. This could be a decisive factor in the low-
income areas where there are problems with access to health
services. Other reports indicate better results (reduction of
HPV prevalence in unvaccinated females by 86–96% versus
7–31%) with a vaccine coverage of 80% in females and males
versus 80% in females only [91], but there is no evidence-
based data available yet.
4. Prevention Strategies of HPV-Related
Cancersinthe Developing Countries
4.1. A Diﬀerent Point of View. The need for cervical cancer
prevention is the greatest in developing countries where
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cancers is the heaviest, and preventive measures have not
been/cannot be implemented consistently. From the point
of view of global justice, the prevention of cervical cancer
should be a priority in countries where its burden is the
heaviest.TheGlobalAllianceforVaccinesandImmunisation
(GAVI) considers HPV vaccines among the vaccines that
would have the biggest impact on the disease burden
in developing countries. Within the developing countries
(and in some developed or middle-income countries), the
situation in rural regions with major problems of access to
health services poses various questions concerning equity
and justice [92]. In the reality of overall scarce resources,
rural regions tend to suﬀer the most [93]. This is exempliﬁed
in how screening has failed to make an impact in developing
countries and especially in rural regions with problems
of access to all cervical cancer prevention health services,
including screening, diagnosis, treatment, and followup [53,
94]. The poor (<50%) acceptance of cervical screening
by a signiﬁcant proportion of females in the younger
birth cohorts has resulted in a comparable loss of impact
with consequent increase in cervical cancer incidence in
the developed countries. In the developing countries the
accessibility of health services is far too low to guarantee
desired impact overall. HPV vaccines oﬀer qualitatively
diﬀerent (primary/complete versus secondary/incomplete
prevention) possibilities for preventing cervical cancer in
women and other HPV-related cancers in both women and
men.
Due to the assortative nature of common sexually
transmitted infections like HPV, the suﬃcient coverage to
produce herd immunity eﬀect is relatively low [95]. In the
case of HPV, with a narrow window of applicability (before
sexual debut), it is advisable to decide early enough if the
vaccine is oﬀered only to females or to both sexes, that is, all
potentialcarriersofHPVinfection.Thequestionispertinent
in all regions where achieving (access to or acceptability of
an HPV vaccine) high vaccine coverage is challenging. The
challenges are numerous varying from ﬁnancial restraints of
access to cultural or religious acceptability of the vaccine.
In addition to access to health services (in this case vacci-
nation or screening), it should be noted that the success of a
vaccination or a screening programme is partly dependent
on decision making by the objects of the intervention or
other parties like parents, spouses, other family members,
inﬂuential persons in the community, and politicians [96].
In the case of HPV, attitudes towards vaccination are more
positive in persons who have more information on the
vaccine, HPV, and the causality between HPV and cancer
[97]. It is probable that those who have the least information
are less likely to participate than those with solid/improved
information. The average, complete nonacceptability does
notexceed10–15%[96–106]butcanbefurtherreducedwith
health education. According to numerous studies, women
and men in general are unaware of the causality between
HPV and cervical cancer, and it can be assumed that the
connection between HPV and HPV-related cancers is even
lessgenerallyknown.AttitudestowardsHPVvaccinationare,
however, generally positive [106] which is probably due to
positive attitudes towards vaccinations in general [107].
HPV is such a common infection that a risk-group inter-
vention alone is not likely to produce good results and have
an impact. A high-risk group strategy based on behavioural
characteristics would also be problematic to implement for
a variety of reasons, most notably the inability to identify
people at risk. Moreover, HPV does not have a tight core
group as many classical STIs [108]. A useful strategy here
might be to implement “add-ons” for risk groups in addition
to a general vaccination programme. In the case of HPV,
there may be two diﬀerent risk groups: those who are at
risk of infection because of risk-taking behaviour and those
who are at risk of nondetection of sequelae because of
geographical diﬀerences in access, that is, rural versus urban
residence. Due to the ubiquitous nature of HPV infection it
is reasonable that the WHO recommendation takes only the
latter risk group into account by recommending starting a
phased introduction in populations who do not have access
to screening [109].
Cervical cancer is associated with poverty on both
the global [3] and regional scalen [110–112]. The same
association can be seen in cancer incidence and mortality
in general [113, 114]. Poverty is the most common source
of inequity along with gender, ethnicity, religion, geography,
age, education, and social status [115–118]. It has been
argued that health inequity in the developing countries
is likely to increase if HPV vaccination programmes are
not implemented [92, 119]. Cervical cancer mortality rate,
which can indicate the eﬀectiveness of screening, diagnosis,
treatment, and followup, is proportionally higher (up to 18
times) in rural than in urban areas [110–112, 120]. People
with low social status living in the developing (or middle-
income) countries and in the rural regions are the least well
oﬀ in the case of HPV-related diseases. This again highly
favours HPV vaccination as a prevention strategy in low-
income areas with special emphasis on regional charac-
teristics.
This regional aspect has its implications in terms of
judging diﬀerent methods and optional preventive strategies
that can guarantee access to and coverage of primary
prevention. In the urban areas the recommended prevention
strategies might be eﬃcient to signiﬁcantly reduce HPV
disease burden because there are fewer problems connected
to access and coverage. The challenges of implementing HPV
vaccination programmes in practice are similar to some
elements of implementing screening programmes, that is,
ﬁnancial constraints, competing health needs, and limited
human resources. The infrastructure and logistical capacity
needed are much more limited in rural regions and will
require investments.
4.2. Optional Strategies for Rural and Urban Regions. The
question is whether we can opt for a single strategy for a
countryoragroupof countriesorweshouldlook atregional
characteristics linked to access in deciding which strategy to
adopt case by case. Malmqvist et al. [121] have stated that
strategies aiming at herd immunity (providing the vaccine to
males and females) might be the best way to prevent cervical
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herdimmunityinthedevelopedcountrieswouldalsoprotect
those who do not have access to the vaccine (or screening) or
who do not accept vaccination or screening. Strategies that
are doable in developed countries may not be practical in
low-resource regions. Thus, it is appealing to contemplate
diﬀerent strategies for rural and urban regions taking into
account access/distance to health services and opting for
regional and/or population subgroup-speciﬁc strategies in
order to achieve the highest possible impact.
In case mass vaccination would be oﬀered, several strate-
gies exist. A few relevant regional or even community-level
strategies from the point of view of developing countries
and/or regions are described as follows:
(1) vaccinating females at the age of 12–15:
(i) unrealistic targeting a coverage of 70%,
(ii) questionable herd immunity eﬀect,
(iii) marginalized females excluded;
(2) vaccinating females when school attendance is at the
highest (10–12 years of age):
(i) unrealistic targeting a coverage of >80%,
(ii) prioritizing vaccinating younger girls before
school attendance drops—need for boosters?
(iii) questionable herd immunity eﬀect,
(iv) marginalized females excluded;
(3) vaccinating females and males at the age of 12–15:
(i) targeting a coverage of >40% in all regions,
(ii) cost eﬀectiveness,
(iii) acceptance of the vaccine for boys?
(iv) marginalization tackled by the herd immunity
eﬀect?
(4) vaccinating females and males when school atten-
dance is at the highest (10–12 years of age):
(I) targeting a coverage of >50% in all regions,
(ii) acceptance of the vaccine for boys?
(iii) marginalization tackled by the herd-immunity
eﬀect.
All strategies would be school based with community
outreach activities in regions where school attendance is
low and equally there would be a need for information
campaignstoadolescents,serviceproviders,decisionmakers,
schools, and parents [122]. Information campaigns for both
sexes with a notion to all HPV-related cancers might further
increase the acceptance of HPV vaccine. It would also be
important to address local or cultural issues which are linked
to vaccines [93].
In terms of HPV vaccine coverage in developed coun-
tries, the highest rates have been achieved by school-based
vaccinationprogrammes[123].School-baseddemonstration
projects have shown promise in terms of coverage and
compliance. In a universal school-based vaccination pro-
gramm the adolescents who go to school may bring also
nonattendeestothevaccinationsite[124].Schoolattendance
of girls has increased in developing countries from 78% in
1990 to 85% in 2005 [125, 126]. Rates of primary school
completion follow closely the enrolment ﬁgures [127]. The
gender gap between boys and girls has disappeared in East
Asia, Latin America, and Eastern and Southern Africa and
is diminishing both in urban and rural regions and within
economic quintiles [125, 127].
The challenges of a school-based programme are many.
School-based programmes may not be feasible if suﬃcient
resources are not allocated to providers [128]. School
attendance in girls during adolescence may be lower than is
needed for eﬀective coverage, and certain high-risk groups
m i g h tn o tb er e a c h e da ta l l[ 124, 129].
TheprojectfundedbyPATH,anAmericanNGO,inPeru,
Uganda, India, and Vietnam reached coverage of 80–95% in
9–14-year-old girls in selected schools demonstrating a high
acceptability of the HPV vaccine [130]. The PATH project
is also producing vital practical information on introducing
HPV vaccines in developing countries (e.g., in certain
cultures parents do not have documentation concerning date
of birth, there may be undue concerns for fertility, emphasis
on cancer prevention, etc.). Even though HPV vaccination
shares many barriers with cervical screening [131], it seems
that barriers linked to acceptation of HPV vaccine might
be easier to deal with. For those females who agreed to be
vaccinated, completion of the three-dose regimen was over
90% in Peru [130]. It is not clear whether vaccination rates
such as these would be achievable in a nonresearch setting.
Optional preventive strategies, regional strategies, or
mixed strategies, oﬀering vaccination only to girls in some
wealthier regions, and to both sexes in certain low-income
regions could tackle the problems linked with coverage and
access. In some areas, it might be more feasible to have
boys vaccinated because of higher school attendance, and
this could lessen problems of coverage even though fewer
girls would be reached. Other preventive acts such as male
circumcision [132]a n du s eo fc o n d o m s[ 133] make this
a problem which has a solution that includes actions by
both males and females. Tackling the problem as gender-
free problem might promote vaccine acceptance and create
political will [128]. Hence, the proposed “add-ons” would
include vaccinating both sexes to achieve maximal coverage
and acceptance. Targeting the early adolescents when school
attendance is at the highest but before sexual debut might
b eap r o b l e m .I nas t u d yc o n d u c t e di nS o u t hA f r i c a ,s o m e
parents expressed their fear that vaccination at 11 years or
older would already be too late [128].
The questions concerning dosage are closely linked with
logistics, vaccine storage, vaccine acceptability, and cost
eﬀectiveness. The present vaccines are administered in three
doses, but it is possible that a two-dose regimen could be
enough to provide protection. This would have a signiﬁcant
eﬀectmainlyoncostsbutequallytovaccineacceptabilityand
accessibility. In a study on Kenyan women, the acceptability
of a three-dose vaccine regimen was only 31% compared to6 Infectious Diseases in Obstetrics and Gynecology
86% for a one-dose regimen [105]. It is known that present
vaccines do not provide eﬀective protection in a one-dose
regimen but a two-dose regimen remains possible.
Further cost-eﬀectiveness studies are needed taking into
account other HPV-related cancers besides cervical cancer.
Regional characteristics and problems linked with access and
coverage should be addressed as well. Vaccination strategies
including catch-up vaccination in older females or address-
ing early adolescents after the sexual debut should be linked
with the most accessible screening and treatment methods
such as the single visit approach (VIA and cryotherapy) to
ensurethatthemeansofpreventionwouldprotectthosewho
may be already HPV infected and for whom the prophylactic
vaccine cannot be eﬀective.
Information about HPV vaccination and HPV-related
cancers continues to emerge, but more research is needed
especially on the long-term impact of vaccination, duration
of protection, male vaccination, and reduction of HPV
transmission. The GAVI Alliance subsidises the provision of
vaccines to the poorest countries and is currently reviewing
HPV vaccine as a candidate for sustainable ﬁnancing. Even
with secured ﬁnancing, there is no simple answer concerning
which strategy should be adopted in the developing coun-
tries.
5. Conclusion
HPV vaccination is the most promising way to prevent
cervical and other HPV-related cancers in developing coun-
tries. The vaccine is eﬀective, safe, and widely accepted.
Vaccinationstrategieshaveanimportanteﬀectonthesuccess
of any vaccination programme. In the case of HPV, it is
crucial to reach at least 70% of females or 40–50% of both
sexes before sexual debut. Currently, only the option of
vaccinating females is recommended by WHO.
Optional preventive strategies, regional strategies, or
mixed strategies in rural low-income regions could solve the
problems linked with HPV vaccination coverage, access, and
acceptability. Regional characteristics aﬀect fundamentally
the feasibility of HPV vaccination strategies as it has already
been proven with screening. Diﬀerences between regions
in terms of access to health services increase the need to
adopt region-speciﬁc HPV vaccination strategies that are not
currently deemed as cost eﬀective. Emerging information
on HPV-related cancers in both women and men and the
feasibility of achieving high vaccine coverage in rural regions
might produce diﬀerent results in terms of cost eﬀectiveness,
andthismightresultasachangeinstrategicaimsandrecom-
mendations.
Targeting rural low-resource regions with speciﬁc vacci-
nation strategies should be a priority from the point of view
of ethics and public health. The number of cervical cancer
cases is estimated to increase dramatically in developing
countries if no intervention is implemented, and the trend
is probably even stronger in regions where access to health
services is limited. Whatever option is chosen, it is vital to
merge any vaccination strategy with appropriate screening
methods and sexual education.
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